Yaron Werber predicts Ascendis will have until March 2027 to convert patients if they lose the ITC patent case, with initial decision expected August 21, 2026.
“if they lose, which is an if, to then, that that goes into effect. And so right now, they're basically racing to convert patients and at the very least, obviously, grow the market because the drug really based on clinical data does look better than BioMarin's. So it's very much a landmark case that's very much patent related, but also very much for patient, benefit, you know, would be considered as well. So we'll see what happens August 21.”
→ Read the source episode
Our resolution criterion
disputableITC issues initial decision on patent infringement by August 21, 2026; if Ascendis loses, injunction would take effect by March 2027
More from Biotech Hangout
Tarsus Pharmaceuticals' Alkias phase three Northstar study for gilderretinol will report data in H2 2029.
Ten X will meet with EMA to explore enriched patient populations for HFpEF drug following failed phase three.
Brian Skorney predicts Lilly's Lp(a) CVOT data may read out in 2029.
Daphne Zohar predicts Heidi Overton's FDA commissioner confirmation hearings will occur after the Senate summer recess.
Eric Schmidt predicts the HARMONY three study for evanesquimab will read out positively in 6-9 months.
Paul Matisse reports Biohaven's KV7 epilepsy drug is on partial clinical hold with phase 3 data coming soon.
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.